Skip to content

Peripheral mechanisms

TL;DR — Peripheral neuropathic pain is not a passive readout of axon loss. Injury changes membrane excitability, ion-channel expression, axonal transport, dorsal-root-ganglion coupling and immune–glial signaling, allowing spontaneous and stimulus-evoked activity to arise from injured and surviving neurons (Baron 2010, PMID 20650402; Cohen 2014, PMID 24500412). Sodium-channel biology is compelling—rare channelopathies prove causal sufficiency—but broad channel blockers have narrow therapeutic windows and phenotype-to-target translation remains incomplete (Wood 2004, PMID 15362153; Dickenson 2021, PMID 33899639). Macrophages, Schwann cells and satellite glia can initiate, maintain or resolve hypersensitivity, with most pathway-specific evidence still preclinical (Inoue 2018, PMID 29416128; Yu 2020, PMID 31937758). The clinically important unit is therefore a changing lesion–neuron–immune circuit, not a single “pain fiber.”

From lesion to ectopic generator

After axotomy, compression, metabolic injury or toxic exposure, spontaneous firing can arise at the injury site, along the axon or in the dorsal-root ganglion (DRG). Demyelination permits abnormal impulse propagation and ephaptic interaction; partial lesions leave intact nociceptors exposed to inflammatory mediators (Berger 2011, PMID 21440003; Finnerup 2021, PMID 32584191).

Process Cellular effect Clinical correlate Evidence boundary
Membrane depolarization Lowers firing threshold Burning/spontaneous pain Human microneurography limited
Ectopic pacemaking Repetitive activity outside terminals Electric shocks/paroxysms Location varies by lesion
Demyelination Conduction slowing/block and cross-talk Loss plus paresthesia Large-fiber tests miss small fibers
Collateral sprouting Reorganized innervation Expanded receptive fields Causality in humans uncertain
Neuroma formation Disorganized regenerating axons Focal percussion sensitivity Not every neuroma is painful
Sympathetic coupling Adrenergic modulation of afferents Autonomic-linked pain in subsets Not universal

Negative and positive signs can arise together: a reduced number of functioning axons produces sensory loss, while surviving neurons become hyperexcitable (Colloca 2017, PMID 28205574).

Voltage-gated sodium channels

NaV channels determine action-potential initiation and propagation. Peripheral nociceptors prominently express NaV1.7, NaV1.8 and NaV1.9; injury can alter density, localization and interacting proteins (Wood 2004, PMID 15362153; Vasylyev 2024, PMID 39378238).

Channel Mechanistic role Human inference Translational issue
NaV1.7 Threshold amplification Gain-of-function causes painful channelopathies; loss causes pain insensitivity Selective blockade has not reproduced genetic analgesia
NaV1.8 Carries tetrodotoxin-resistant current Supports repetitive nociceptor firing Interaction with NaV1.7 may matter more than either alone
NaV1.9 Persistent subthreshold current Variants can produce painful or painless phenotypes Small therapeutic window and phenotype heterogeneity
NaV1.3 Developmental channel re-expressed after injury in models Proposed ectopic-excitability contributor Human causal evidence sparse

NaV1.7/NaV1.8 interplay can drive hyperexcitability, arguing against a one-channel/one-symptom model (Vasylyev 2024, PMID 39378238). A defined NaV1.7 domain can modulate chronic-pain signaling in experimental systems, but clinical target validation remains pending (Gomez 2023, PMID 37498871).

Dynamic-clamp experiments make the interaction quantitative. In small DRG neurons expressing the erythromelalgia-associated NaV1.7-L848H variant, NaV1.8 open probability at the action-potential threshold was ninefold higher than NaV1.7 open probability; reducing modeled NaV1.8 current by 25–50% increased rheobase and reduced firing probability (Vasylyev 2024, PMID 39378238). This is mechanistic evidence in neurons, not a clinical effect estimate, but it explains why partial inhibition of one channel can matter only in a channel-defined excitability state.

The repeated failure of sodium-channel modulators to become broadly effective reflects state dependence, insufficient subtype selectivity, central/cardiac toxicity, access to the relevant neuronal compartment and failure to enrich trials for channel-driven phenotypes (Dickenson 2021, PMID 33899639).

Venom and toxin pharmacology has supplied subtype-selective channel probes and structural templates, but potency and selectivity in an experimental preparation do not guarantee safe access to the relevant human nociceptor compartment (Cardoso 2018, PMID 28749537).

Human genetics supports enrichment but also exposes its limits. In a UK cohort selected for extreme sensory gain or loss, medically actionable variants were found in 12% of 205 participants; variants were concentrated in voltage-gated sodium-channel genes, but exploratory associations also implicated growth, axonal-transport and TRP-channel genes (Themistocleous 2023, PMID 36895957). Selection for an extreme phenotype raises yield and cannot be extrapolated to unselected painful neuropathy.

Calcium and potassium channels

The α2δ subunit of voltage-gated calcium channels is upregulated after injury and is the binding target of gabapentin and pregabalin. These drugs reduce transmitter release rather than acting as direct GABA agonists; their modest NNTs indicate that α2δ-dependent transmission is not dominant in every patient (Finnerup 2015, PMID 25575710).

Potassium-current loss prolongs depolarization and promotes repetitive firing. KCNQ and other channel families are plausible targets, but a mechanism review cautions that animal injury signatures do not automatically define human treatment-responsive subgroups (Bannister 2020, PMID 31914896).

The dorsal-root ganglion as an amplifier

The DRG contains sensory-neuron somata, satellite glial cells, resident macrophages and a permeable microvascular environment. It can generate ectopic activity and coordinate immune signaling remote from the distal lesion (Guha 2016, PMID 27399376).

DRG component Candidate contribution
Sensory-neuron soma Spontaneous discharge and altered transcription
Satellite glial cell Gap-junction and cytokine signaling around somata
Macrophage Initiation, persistence or resolution depending on state
Vasculature Exposure to circulating inflammatory/metabolic factors
Sympathetic fibers Post-injury coupling and adrenergic sensitivity

DRG stimulation may exploit the ganglion’s filtering properties, but proposed mechanisms—conduction block, normalization of excitability, altered filtering and central effects—remain incompletely separated (Graham 2022, PMID 34425252; Abd-Elsayed 2024, PMID 38612402).

Neuroimmune signaling

Peripheral nerve injury recruits neutrophils, monocytes/macrophages and adaptive immune cells while activating Schwann and satellite glial cells. Released cytokines, chemokines, growth factors, lipids and purines change neuronal thresholds (Inoue 2018, PMID 29416128; Fiore 2023, PMID 36859719).

Signal/cell Experimental observation Translation status
DRG macrophages Contribute to initiation and persistence after injury Human DRG tissue localizes ADORA3 to perineuronal macrophages, but no validated patient-selection marker exists
CXCL10/CXCR3 DRG signaling worsened pain in mice Preclinical target
Microglia Sex-, time- and model-dependent contribution Human imaging cannot identify pathway causally
Pro-resolving immune programs Can terminate inflammation and hypersensitivity Therapeutic timing unresolved
Schwann-cell injury response Debris clearance, repair and inflammatory signaling Protective and harmful roles coexist

Mouse work demonstrates that DRG macrophages can contribute to both onset and persistence, making indiscriminate immune suppression biologically unattractive (Yu 2020, PMID 31937758). The field is moving from “inflammation causes pain” toward phase- and cell-state-specific immune programs (Fiore 2023, PMID 36859719).

Human-tissue evidence narrows the translation gap without closing it: ADORA3 transcripts were localized to perineuronal macrophages rather than sensory neurons in human DRG, supporting a macrophage-linked therapeutic hypothesis (Sapio 2024, PMID 38691673). A targeted PubMed search on 2026-08-30 found no externally validated macrophage marker that selects patients or predicts analgesic response.

Schwann-cell–axon metabolic coupling

Schwann cells are not passive insulation. They provide trophic and metabolic support, regulate myelin, clear debris and instruct repair; in diabetes, hyperglycemia and dyslipidemia can disrupt axon–Schwann-cell bioenergetic exchange before complete axon loss (Feldman 2017, PMID 28334605). Recent synthesis separates apoptosis, autophagy, pyroptosis, ferroptosis and necroptosis as candidate Schwann-cell injury programs, while emphasizing that most pathway-specific interventions remain preclinical (Wu 2024, PMID 39193373).

Schwann-cell state Potential benefit Potential pain-promoting consequence
Homeostatic/myelinating Axonal support and saltatory conduction Metabolic dependence makes axons vulnerable when support fails
Injury response Debris clearance and regeneration Cytokine/chemokine release can lower nociceptor thresholds
Demyelinating Enables remyelination program Conduction failure and ectopic/ephaptic activity
Senescent or metabolically stressed May contain damage Persistent inflammatory and bioenergetic stress

The resulting controversy is not whether Schwann cells matter, but whether a measured signal marks protective repair or maladaptive persistence at the sampled time point. A treatment that suppresses the early injury response could reduce inflammation yet impair later regeneration.

Small fibers: loss, sensitization or both

Small-fiber neuropathy affects thinly myelinated Aδ and unmyelinated C fibers, producing burning pain, thermal loss and autonomic symptoms while routine nerve-conduction studies remain normal (Devigili 2020, PMID 32654574).

Reduced intraepidermal nerve-fiber density supports structural small-fiber loss but does not measure ectopic firing or establish why the remaining fibers hurt. Skin biopsy is reliable when age-matched norms and laboratory quality controls are used (Lauria 2010, PMID 20642627).

Measurement Captures Misses
Skin biopsy Fiber density/morphology Real-time excitability and central amplification
Thermal QST Functional pathway perception Lesion localization and etiologic specificity
Autonomic testing Sudomotor/cardiovascular small-fiber function Purely somatic small-fiber disease
Corneal confocal microscopy Corneal small-fiber structure Direct equivalence to painful body territory
Nerve conduction Large-fiber physiology C and most Aδ fibers

Diagnostic studies remain heterogeneous: only 14% of idiopathic small-fiber neuropathy studies used the most common combined symptom, large-fiber exclusion and reduced-density criteria (Haroutounian 2021, PMID 32989823).

Etiology changes the injury program

Etiology Dominant peripheral insults Clinical implication
Diabetes Metabolic, mitochondrial and microvascular stress Pain can precede large-fiber abnormalities
Chemotherapy Agent-specific axonal, mitochondrial, microtubule or DRG toxicity “CIPN” is mechanistically plural
Zoster Viral ganglionitis and axonal loss Prevention addresses the causal insult
Trauma/surgery Transection, traction, compression, neuroma Focal generator may be anatomically targetable
Entrapment Ischemia, demyelination and axonal loss Decompression can change phenotype
Channelopathy Primary excitability defect Genotype can be mechanistically decisive

Diabetic neuropathy links hyperglycemia, lipid dysmetabolism, mitochondrial dysfunction and microvascular injury; type 1 and type 2 prevention responses differ (Feldman 2019, PMID 31197153). CIPN mechanisms vary across platinum agents, taxanes, vinca alkaloids, proteasome inhibitors and newer therapies (Staff 2017, PMID 28486769; Starobova 2017, PMID 28620280).

The diabetic mechanism debate has shifted from a glucose-only cascade to interacting substrate and support failures. Structural vulnerability of long axons, mitochondrial energetics, lipid injury, insulin signaling and Schwann-cell support can all converge on distal axon degeneration (Feldman 2017, PMID 28334605). Improved glycemic control therefore has strong biological logic without implying that established painful neuropathy is simply reversible glucotoxicity.

Peripheral-to-central transition

Persistent afferent barrage increases spinal glutamate signaling, recruits glia, weakens inhibition and changes descending control. Once central circuitry is altered, blocking the peripheral generator may incompletely reverse ongoing pain (Latremoliere 2009, PMID 19712899).

This transition is neither inevitable nor binary. Entrapment-neuropathy surgery changed thermal and mechanical sensory phenotype at six months, showing that at least some QST abnormalities are state-dependent and reversible (Kennedy 2021, PMID 33769367).

Therapeutic implications

Mechanism hypothesis Existing probe What response can—and cannot—show
Ectopic sodium current Lidocaine/mexiletine/carbamazepine Supports excitability dependence; does not identify channel subtype
α2δ-mediated release Gabapentin/pregabalin Supports synaptic contribution; response is not diagnostic
Focal peripheral generator Local anesthetic block Temporary response supports peripheral drive but includes placebo/spread
TRPV1-expressing terminals Capsaicin 8% Defunctionalizes local nociceptors; benefit does not prove TRPV1 cause
DRG circuit DRG stimulation Modulates network; mechanism remains multi-level

Mechanism-based therapy remains a goal rather than a validated prescribing system. Similar symptoms can arise from different pathways, and the same lesion can generate different sensory phenotypes (Binder 2015, PMID 26307854; Reimer 2014, PMID 24670811).

Open questions

  • Which human biomarker identifies pain maintained by ectopic peripheral firing rather than downstream central circuitry? (Bannister 2020, PMID 31914896)
  • Can NaV-target trials enrich by genotype, microneurography or response to a short-acting blocker? (Dickenson 2021, PMID 33899639)
  • Which macrophage states maintain pain and which resolve it at each disease phase? (Yu 2020, PMID 31937758; Fiore 2023, PMID 36859719)
  • Does small-fiber loss cause pain, reflect prior injury, or mark a subgroup whose surviving fibers are hyperexcitable? (Lauria 2010, PMID 20642627)
  • When does removal of peripheral drive reverse central plasticity, and when is it too late? (Kennedy 2021, PMID 33769367)

References

  1. Baron R, et al. Neuropathic pain: diagnosis, mechanisms and treatment. Lancet Neurol. 2010;9:807-819. PMID 20650402
  2. Cohen SP, Mao J. Neuropathic pain: mechanisms and clinical implications. BMJ. 2014;348:f7656. PMID 24500412
  3. Colloca L, et al. Neuropathic pain. Nat Rev Dis Primers. 2017;3:17002. PMID 28205574
  4. Finnerup NB, et al. Neuropathic pain: from mechanisms to treatment. Physiol Rev. 2021;101:259-301. PMID 32584191
  5. Berger JV, et al. Cellular and molecular insights into neuropathy-induced hypersensitivity. Brain Res Rev. 2011;67:282-310. PMID 21440003
  6. Wood JN, et al. Voltage-gated sodium channels and pain pathways. J Neurobiol. 2004;61:55-71. PMID 15362153
  7. Vasylyev DV, et al. Interplay of Nav1.8 and Nav1.7 channels drives neuronal hyperexcitability in neuropathic pain. J Gen Physiol. 2024;156:e202413596. PMID 39378238
  8. Dickenson A. Why are sodium channel modulators not yet pharmacotherapeutic trailblazers for neuropathic pain? Expert Opin Pharmacother. 2021;22:1635-1637. PMID 33899639
  9. Gomez K, Stratton HJ, Duran P, et al. Identification and targeting of a unique NaV1.7 domain driving chronic pain. Proc Natl Acad Sci U S A. 2023;120:e2217800120. PMID 37498871
  10. Liao S, Liu T, Yang R, et al. Structure and Function of Sodium Channel Nav1.3 in Neurological Disorders. Cell Mol Neurobiol. 2023;43:575-584. PMID 35332400
  11. Finnerup NB, et al. Pharmacotherapy for neuropathic pain in adults. Lancet Neurol. 2015;14:162-173. PMID 25575710
  12. Bannister K, et al. Neuropathic pain: mechanism-based therapeutics. Annu Rev Pharmacol Toxicol. 2020;60:257-274. PMID 31914896
  13. Guha D, et al. Dorsal root ganglion in chronic neuropathic pain. Neurosurgery. 2016;63 Suppl 1:118-126. PMID 27399376
  14. Graham RD, Sankarasubramanian V, Lempka SF. Dorsal Root Ganglion Stimulation for Chronic Pain: Hypothesized Mechanisms of Action. J Pain. 2022;23:196-211. PMID 34425252
  15. Abd-Elsayed A, Vardhan S, Aggarwal A, et al. Mechanisms of Action of Dorsal Root Ganglion Stimulation. Int J Mol Sci. 2024;25. PMID 38612402
  16. Inoue K, Tsuda M. Microglia in neuropathic pain: cellular and molecular mechanisms and therapeutic potential. Nat Rev Neurosci. 2018;19:138-152. PMID 29416128
  17. Fiore NT, Debs SR, Hayes JP, et al. Pain-resolving immune mechanisms in neuropathic pain. Nat Rev Neurol. 2023;19:199-220. PMID 36859719
  18. Yu X, et al. DRG macrophages contribute to initiation and persistence. Nat Commun. 2020;11:264. PMID 31937758
  19. Kong YF, Sha WL, Wu XB, et al. CXCL10/CXCR3 Signaling in the DRG Exacerbates Neuropathic Pain in Mice. Neurosci Bull. 2021;37:339-352. PMID 33196963
  20. Devigili G, et al. Clinical diagnosis and management of small fiber neuropathy. Expert Rev Neurother. 2020;20:967-980. PMID 32654574
  21. Lauria G, et al. EFNS/PNS skin-biopsy guideline. Eur J Neurol. 2010;17:903-912. PMID 20642627
  22. Haroutounian S, et al. Diagnostic criteria for idiopathic small fiber neuropathy. Muscle Nerve. 2021;63:170-177. PMID 32989823
  23. Feldman EL, et al. Diabetic neuropathy. Nat Rev Dis Primers. 2019;5:41. PMID 31197153
  24. Staff NP, et al. Chemotherapy-induced peripheral neuropathy: current review. Ann Neurol. 2017;81:772-781. PMID 28486769
  25. Starobova H, Vetter I. Pathophysiology of chemotherapy-induced peripheral neuropathy. Front Mol Neurosci. 2017;10:174. PMID 28620280
  26. Latremoliere A, Woolf CJ. Central sensitization. J Pain. 2009;10:895-926. PMID 19712899
  27. Kennedy DL, Vollert J, Ridout D, et al. Responsiveness of quantitative sensory testing-derived sensory phenotype to disease-modifying intervention in patients with entrapment neuropathy: a longitudinal study. Pain. 2021;162:2881-2893. PMID 33769367
  28. Binder A, Baron R. Mechanism-based therapy for neuropathic pain-a concept in danger? Pain. 2015;156:2113-2114. PMID 26307854
  29. Reimer M, Helfert SM, Baron R. Phenotyping neuropathic pain patients: implications for individual therapy and clinical trials. Curr Opin Support Palliat Care. 2014;8:124-9. PMID 24670811
  30. Themistocleous AC, et al. Investigating genotype-phenotype relationship of extreme neuropathic pain disorders in a UK national cohort. Brain Commun. 2023;5:fcad037. PMID 36895957
  31. Feldman EL, et al. New horizons in diabetic neuropathy: mechanisms, bioenergetics, and pain. Neuron. 2017;93:1296-1313. PMID 28334605
  32. Wu L, et al. Diabetic peripheral neuropathy based on Schwann cell injury: mechanisms of cell death regulation and therapeutic perspectives. Front Endocrinol (Lausanne). 2024;15:1427679. PMID 39193373
  33. Cardoso FC, Lewis RJ. Sodium channels and pain: from toxins to therapies. Br J Pharmacol. 2018;175:2138-2157. PMID 28749537
  34. Sapio MR, Staedtler ES, King DM, et al. Analgesic candidate adenosine A3 receptors are expressed by perineuronal peripheral macrophages in human dorsal root ganglion and spinal cord microglia. Pain. 2024;165:2323-2343. PMID 38691673